Literature DB >> 8097284

Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.

B Lemmer1, L Langer, T Ohm, J Bohl.   

Abstract

beta-Adrenoceptor density and beta 1- and beta 2-subtype distribution were examined in hippocampi and cerebella from patients with Alzheimer's disease (AD/SDAT). Tissues from age-, sex and post-mortem delay matched non-demented patients served as controls. The total beta-adrenoceptor density as evaluated in saturation experiments with the hydrophilic radioligand [3H]CGP 12177 was higher in hippocampal (36-39 fmol/mg protein) than cerebellar tissues (20-21 fmol/mg), however, no differences were found in either brain region between AD/SDAT patients and controls. Subtype distribution using the highly selective beta 1-adrenoceptor antagonist CGP 20712A revealed a slightly higher proportion of beta 1-adrenoceptors in hippocampus (26%-27%) than in cerebellum (20%-21%) with, again, no difference between AD/SDAT and controls. We recently described a 40% reduction in basal and stimulated adenylyl cyclase activity in post-mortem hippocampus of AD/SDAT patients, a brain region greatly affected by the disease, the present data now demonstrate that this disease-related effect is not mirrored by a similar change in beta-adrenoceptor density nor in subtype distribution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097284     DOI: 10.1007/bf00169270

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

Review 1.  Drug treatment of Alzheimer's disease.

Authors:  J K Cooper
Journal:  Arch Intern Med       Date:  1991-02

2.  Beta-adrenoceptors in human brain labelled with [3H]dihydroalprenolol and [3H]CGP 12177.

Authors:  F De Paermentier; S C Cheetham; M R Crompton; R W Horton
Journal:  Eur J Pharmacol       Date:  1989-08-29       Impact factor: 4.432

3.  CGP 20712 A: a useful tool for quantitating beta 1- and beta 2-adrenoceptors.

Authors:  D J Dooley; H Bittiger; N C Reymann
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

4.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

5.  Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features.

Authors:  A Kumar; M B Schapiro; J V Haxby; C L Grady; R P Friedland
Journal:  J Psychiatr Res       Date:  1990       Impact factor: 4.791

Review 6.  Treatment of Alzheimer's disease with cholinergic drugs.

Authors:  V Kumar; M Calache
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-01

7.  Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus.

Authors:  R N Kalaria; A C Andorn; M Tabaton; P J Whitehouse; S I Harik; J R Unnerstall
Journal:  J Neurochem       Date:  1989-12       Impact factor: 5.372

8.  Quantitative assessment of central beta 1- and beta 2-adrenoceptor regulation using CGP 20712 A.

Authors:  D J Dooley; H Bittiger
Journal:  J Pharmacol Methods       Date:  1987-09

9.  Studies on neurotransmitter binding in senile dementia. Comparison of Alzheimer's and mixed vascular-Alzheimer's dementias.

Authors:  S Jenni-Eiermann; H P von Hahn; C G Honegger; J Ulrich
Journal:  Gerontology       Date:  1984       Impact factor: 5.140

10.  Diminished glucose transport in Alzheimer's disease: dynamic PET studies.

Authors:  W J Jagust; J P Seab; R H Huesman; P E Valk; C A Mathis; B R Reed; P G Coxson; T F Budinger
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

View more
  4 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 3.  Noradrenergic dysfunction in Alzheimer's disease.

Authors:  Mary Gannon; Pulin Che; Yunjia Chen; Kai Jiao; Erik D Roberson; Qin Wang
Journal:  Front Neurosci       Date:  2015-06-17       Impact factor: 4.677

Review 4.  Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies.

Authors:  Cody Slater; Qi Wang
Journal:  Clin Transl Med       Date:  2021-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.